File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production

TitleAdiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production
Authors
KeywordsAdipokines
Hyperglycemia
Obesity
Thrombotic dieases
Issue Date2007
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.lww.com/product/?1079-5642
Citation
Arteriosclerosis, Thrombosis, And Vascular Biology, 2007, v. 27 n. 12, p. 2777-2782 How to Cite?
AbstractOBJECTIVE - The purpose of this study was to examine the effects of PPAR-γ agonist rosiglitazone, relative to sulfonylureas, on circulating levels of adiponectin and the prothrombotic factor, plasminogen activator inhibitor (PAI)-1, in type 2 diabetic patients, and to investigate, in animal models, whether the antithrombotic action of rosiglitazone was mediated through adiponectin. METHODS AND RESULTS - Our clinical study (n=64) showed that after 24-week add-on therapy, the rosiglitazone group had a greater mean reduction in plasma PAI-1 levels (25%, versus 12% in sulfonylurea group, P=0.002). Stepwise multiple linear regression analysis identified the reduction in plasma fasting glucose and the rise in adiponectin levels to be independently associated with the reduction in PAI-I concentration in the rosiglitazone-treated patients. Rosiglitazone (20 mg/kg/d) reduced adipose tissue PAI-1 mRNA expression and its plasma levels in wild-type C57 mice with diet-induced obesity (P<0.001), but this suppressive effect was attenuated in adiponectin knockout mice. Adenovirus-mediated overexpression of adiponectin led to a significant suppression of adipose tissue PAI-1 expression and its circulating concentrations in db/db diabetic mice. Our in vitro study demonstrated that recombinant adiponectin directly inhibited PAI-1 production in 3T3-L1 adipocytes. CONCLUSIONS - The antithrombotic effect of rosiglitazone is mediated, at least in part, through the suppressive effect of adiponectin on PAI-1 production. © 2007 American Heart Association, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/77682
ISSN
2023 Impact Factor: 7.4
2023 SCImago Journal Rankings: 2.582
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHoo, RLCen_HK
dc.contributor.authorChow, WSen_HK
dc.contributor.authorYau, MHen_HK
dc.contributor.authorXu, Aen_HK
dc.contributor.authorTso, AWKen_HK
dc.contributor.authorTse, HFen_HK
dc.contributor.authorFong, CHYen_HK
dc.contributor.authorTam, Sen_HK
dc.contributor.authorChan, Len_HK
dc.contributor.authorLam, KSLen_HK
dc.date.accessioned2010-09-06T07:34:34Z-
dc.date.available2010-09-06T07:34:34Z-
dc.date.issued2007en_HK
dc.identifier.citationArteriosclerosis, Thrombosis, And Vascular Biology, 2007, v. 27 n. 12, p. 2777-2782en_HK
dc.identifier.issn1079-5642en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77682-
dc.description.abstractOBJECTIVE - The purpose of this study was to examine the effects of PPAR-γ agonist rosiglitazone, relative to sulfonylureas, on circulating levels of adiponectin and the prothrombotic factor, plasminogen activator inhibitor (PAI)-1, in type 2 diabetic patients, and to investigate, in animal models, whether the antithrombotic action of rosiglitazone was mediated through adiponectin. METHODS AND RESULTS - Our clinical study (n=64) showed that after 24-week add-on therapy, the rosiglitazone group had a greater mean reduction in plasma PAI-1 levels (25%, versus 12% in sulfonylurea group, P=0.002). Stepwise multiple linear regression analysis identified the reduction in plasma fasting glucose and the rise in adiponectin levels to be independently associated with the reduction in PAI-I concentration in the rosiglitazone-treated patients. Rosiglitazone (20 mg/kg/d) reduced adipose tissue PAI-1 mRNA expression and its plasma levels in wild-type C57 mice with diet-induced obesity (P<0.001), but this suppressive effect was attenuated in adiponectin knockout mice. Adenovirus-mediated overexpression of adiponectin led to a significant suppression of adipose tissue PAI-1 expression and its circulating concentrations in db/db diabetic mice. Our in vitro study demonstrated that recombinant adiponectin directly inhibited PAI-1 production in 3T3-L1 adipocytes. CONCLUSIONS - The antithrombotic effect of rosiglitazone is mediated, at least in part, through the suppressive effect of adiponectin on PAI-1 production. © 2007 American Heart Association, Inc.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.lww.com/product/?1079-5642en_HK
dc.relation.ispartofArteriosclerosis, Thrombosis, and Vascular Biologyen_HK
dc.rightsArteriosclerosis, Thrombosis, and Vascular Biology. Copyright © Lippincott Williams & Wilkins.en_HK
dc.subjectAdipokinesen_HK
dc.subjectHyperglycemiaen_HK
dc.subjectObesityen_HK
dc.subjectThrombotic dieasesen_HK
dc.subject.mesh3T3-L1 Cellsen_HK
dc.subject.meshAdenoviridae - geneticsen_HK
dc.subject.meshAdipocytes - metabolismen_HK
dc.subject.meshAdiponectin - blood - genetics - metabolismen_HK
dc.subject.meshAdipose Tissue - drug effects - metabolismen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshBlood Glucose - drug effectsen_HK
dc.subject.meshDiabetes Mellitus, Type 2 - blood - drug therapy - metabolismen_HK
dc.subject.meshDietary Fats - administration & dosageen_HK
dc.subject.meshDisease Models, Animalen_HK
dc.subject.meshFibrinolytic Agents - pharmacology - therapeutic useen_HK
dc.subject.meshGenetic Vectorsen_HK
dc.subject.meshHumansen_HK
dc.subject.meshHypoglycemic Agents - pharmacology - therapeutic useen_HK
dc.subject.meshMiceen_HK
dc.subject.meshMice, Inbred C57BLen_HK
dc.subject.meshMice, Knockouten_HK
dc.subject.meshObesity - blood - metabolismen_HK
dc.subject.meshPPAR gamma - agonists - metabolismen_HK
dc.subject.meshPlasminogen Activator Inhibitor 1 - blood - genetics - metabolismen_HK
dc.subject.meshRNA, Messenger - metabolismen_HK
dc.subject.meshRecombinant Proteins - metabolismen_HK
dc.subject.meshSerpin E2en_HK
dc.subject.meshSerpins - blood - metabolismen_HK
dc.subject.meshSulfonylurea Compounds - pharmacology - therapeutic useen_HK
dc.subject.meshThiazolidinediones - pharmacology - therapeutic useen_HK
dc.subject.meshTransduction, Geneticen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleAdiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 productionen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1079-5642&volume=27&spage=2777&epage=82&date=2007&atitle=Adiponectin+mediates+the+suppressive+effect+of+rosiglitazone+on+plasminogen+activator+inhibitor-1+productionen_HK
dc.identifier.emailHoo, RLC: rubyhoo@hkucc.hku.hken_HK
dc.identifier.emailXu, A: amxu@hkucc.hku.hken_HK
dc.identifier.emailTso, AWK: awk.tso@gmail.comen_HK
dc.identifier.emailTse, HF: hftse@hkucc.hku.hken_HK
dc.identifier.emailLam, KSL: ksllam@hku.hken_HK
dc.identifier.authorityHoo, RLC=rp01334en_HK
dc.identifier.authorityXu, A=rp00485en_HK
dc.identifier.authorityTso, AWK=rp00535en_HK
dc.identifier.authorityTse, HF=rp00428en_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1161/ATVBAHA.107.152462en_HK
dc.identifier.pmid17932317-
dc.identifier.scopuseid_2-s2.0-36348931579en_HK
dc.identifier.hkuros140649en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-36348931579&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume27en_HK
dc.identifier.issue12en_HK
dc.identifier.spage2777en_HK
dc.identifier.epage2782en_HK
dc.identifier.isiWOS:000251143300044-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridHoo, RLC=6602369766en_HK
dc.identifier.scopusauthoridChow, WS=7402281153en_HK
dc.identifier.scopusauthoridYau, MH=9233223900en_HK
dc.identifier.scopusauthoridXu, A=7202655409en_HK
dc.identifier.scopusauthoridTso, AWK=6701371436en_HK
dc.identifier.scopusauthoridTse, HF=7006070805en_HK
dc.identifier.scopusauthoridFong, CHY=14033917100en_HK
dc.identifier.scopusauthoridTam, S=7202037323en_HK
dc.identifier.scopusauthoridChan, L=24439401800en_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK
dc.identifier.issnl1079-5642-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats